| Dr Juan Gabriel Ortiz, PHARMD | |
|
228 Calle Colon, Aguada, PR 00602-3224 | |
| (787) 868-2135 | |
| (787) 868-2933 |
| Full Name | Dr Juan Gabriel Ortiz |
|---|---|
| Gender | Male |
| Speciality | Pharmacist - Pharmacist Clinician (phc)/ Clinical Pharmacy Specialist |
| Location | 228 Calle Colon, Aguada, Puerto Rico |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083119036 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1835P0018X | Pharmacist - Pharmacist Clinician (phc)/ Clinical Pharmacy Specialist | 6515 (Puerto Rico) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Juan Gabriel Ortiz, PHARMD 228 Calle Colon, Aguada, PR 00602-3224 Ph: (787) 868-2135 | Dr Juan Gabriel Ortiz, PHARMD 228 Calle Colon, Aguada, PR 00602-3224 Ph: (787) 868-2135 |
News Archive
US Bioservices, a specialty pharmacy that is a part of AmerisourceBergen, today announced that it has been selected by Verastem OncologyTM to dispense COPIKTRA (duvelisib) capsules.
Adolescent girls and young women can and will use HIV prevention products with consistency, according to interim results of a study of two different methods: daily use of the antiretroviral (ARV) tablet Truvada as oral pre-exposure prophylaxis (PrEP) and the monthly dapivirine vaginal ring, a new HIV prevention product currently under regulatory review in several countries.
Our bodies were designed to be active. The human body is not meant to spend long periods of time sitting but that's what our modern lives have led us to do. The result has been the increase in obesity seen across the world, and up to 20 other conditions including cardiovascular disease and diabetes.
Cell Therapeutics, Inc. today announced that it has entered into an agreement to sell $21.0 million of shares of its Series 5 Preferred Stock in a registered offering to three institutional investors (collectively, the "Initial Purchasers"). Each share of Series 5 Preferred Stock is convertible at the option of the holder, at any time during its existence, into 2,500 shares of common stock at a conversion price of $0.40 per share of common stock, for a total of 52,500,000 shares of common stock.
An Oklahoma Medical Research Foundation scientist has discovered that certain sugars produced by the body play an important role in the development of colitis and, ultimately, colon cancer. The new finding could potentially lead to therapies for ulcerative colitis, Crohn's disease and colon cancer.
› Verified 4 days ago
Mrs. Rosa H Chaparro, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 166 Calle Colon, Aguada, PR 00602 Phone: 787-868-4940 Fax: 787-868-4940 | |
Aymee S Caro, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: Hc 58 Box 13656, Aguada, PR 00602 Phone: 787-868-0959 Fax: 787-868-0959 | |
Julissa Cardona, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 162 Calle Marina, Aguada, PR 00602 Phone: 787-868-5890 | |
Dr. Eileen Santiago, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2 Calle Colon Ste 15, Aguada, PR 00602 Phone: 787-868-9495 | |
Mrs. Brenda Enid Cordero Sanchez, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: Hc 3 Box 32654, Aguada, PR 00602 Phone: 787-560-6554 | |
Dr. Naray Miranda, PHARM. D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: Bo Asomante 1928 Carr 115, Aguada, PR 00602 Phone: 787-868-7711 |